7th November 2016
Innovative biotechnology company, Axim Biotechnologies Inc has appointed Grayling in the US to support its Investor Relations and Public Relations’ needs.
Axim Biotechnologies is engaged in the research and development, and production of pharmaceutical, nutriceutical and cosmetic products, as well as the procurement of genetically and nano-controlled active ingredients. The company’s particular focus is on the development of treatments for pain, spasticity, anxiety and other medical disorders using cannabinoids-based products. Pharmaceutical R&D aims to deliver systems and active pharmaceutical ingredients for treating conditions such as Parkinson's disease, Alzheimer's disease, restless leg syndrome and Crohn's disease.
Presently, the company is conducting clinical studies of MedChewRx, a pharmaceutical chewing gum containing cannabinoids. The company is in the process of getting FDA and EMA regulatory approval to launch this product in 2017, and it is in regard to this that Grayling is providing support.
Grayling’s efforts will be driven by New York based executive vice president, Lucia Domville. She says: “This is a fascinating company that is really pushing the boundaries with its research, and we are thrilled to be their partner.”
15th March 2019
In light of the next round of elections coming up in Spain, Grayling Madrid hosted a political round table event on urban mobility to give attendees the opportunity to hear from key political actors...Read More
14th March 2019
Electric scooter sharing company hive has appointed our team in Warsaw to develop and implement a communications strategy for its entry on to the Polish market. Our scope of work covers everything...Read More
11th March 2019
On 14 March the Grayling Brexit Unit in Brussels will be hosting the latest edition of their “Brexit Club” meetings with Jennifer Rankin, the Brussels correspondent for UK newspaper, The...Read More